Skip to main content

Lonza Group AG Value Stock - Dividend - Research Selection

Lonza Group AG

ISIN: CH0013841017, WKN: 928619

Market price date: 16.07.2021
Market price: 658,40 CHF

Lonza Group AG Fundamental data and company key figures of the share

Annual reports in CHF
Key figures 07-08-2020
Cash flow
Net operating cash flow 986.000.000
Capital Expenditures -757.000.000
Free cash flow 229.000.000
Balance sheet
Total Equity 6.565.000.000
Liabilities & Shareholders equity 13.841.000.000
Income statement
Net income 756.000.000
Eps (diluted) 10,140
Diluted shares outstanding 74.000.000
Net sales/revenue 5.920.000.000

Fundamental ratios calculated on: 16-07-2021

Key figures 16-07-2021
Cash flow
P/C 49,41
P/FC 212,76
Balance sheet
Income statement
Div. Yield0,00%

Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.

Market Capitalization49.909.444.608,00 USD
Raw Data SourceIFRS in Millionen CHF
Stock Split2017-05-02,407.000000/377.000000; 2002-04-03,10.000000/1.000000

Description of the company

Lonza Group Ltd supplies products and services to the pharmaceutical, biotech, and specialty ingredients markets worldwide. The company operates through two segments, Pharma&Biotech and Specialty Ingredients. It offers products and services from the custom development and manufacturing of active pharmaceutical ingredients to dosage forms for the pharma and consumer health, and nutrition industries, as well as develops cell and gene therapies. The company also provides drinking water sanitizers, nutraceuticals, antidandruff agents, and other personal care ingredients; and agricultural products and advanced coatings and composites, as well as microbial control solutions that combat dangerous viruses, bacteria, and other pathogens. Lonza Group Ltd was founded in 1897 and is headquartered in Basel, Switzerland.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources::,,